Change of lacrimal gland, ocular surface, and tear inflammatory cytokines in patients with thyroid eye disease before and after anti-inflammation therapy

Change of lacrimal gland, ocular surface, and tear inflammatory cytokines in patients with thyroid eye disease before and after high-dose glucocorticoids treatment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026155

Enrollment

Unknown

Registered

2019-09-24

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid eye disease

Interventions

TED group:high-dose glucocorticoids

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) patients consented to participate in the study; 2) aged 18-70 years; 3) diagnosed with active moderate-to-severe TED based on Bartleys criteria; 4) patients needed to received intravenous methylprednisolone.

Exclusion criteria

Exclusion criteria: 1) inactive TED and sight-threatening TED; 2) history of ocular surface disorders such as dry eye, allergic conjunctivitis, and pterygium; 3) history of ocular surgery, and 4)anyone who received medications that may affect ocular surface parameters including systematic immune disease; 5) contact lens wearing; 6) topical anti-glaucoma drug use.

Design outcomes

Secondary

Measure	Time frame
OSDI score;cornea flurescein stain;tear break-up time;fundus examination;intraocular pressure;Snellen best corrected visual acuity;	—

Primary

Measure	Time frame
lacrimal gland;	—

Countries

China

Contacts

Public ContactYi Cui

Fujian Medical University Union Hospital

oph_cy@163.com+86 18905913369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026